Obsessive-compulsive disorder (OCD) is an important mental disorder owing to its prevalence and associated disability, and because it is a key example of a set of conditions known as obsessive-compulsive and related disorders (OCRDs; Fig. 1 ). OCD is characterized by the presence of obsessions and/or compulsions. Obsessions are repetitive and persistent thoughts, images, impulses or urges that are intrusive and unwanted, and are com monly associated with anxiety. Compulsions are repeti tive behaviours or mental acts that the individual feels driven to perform in response to an obsession accord ing to rigid rules, or to achieve a sense of 'complete ness' . Children might have difficulty in identifying or describing obsessions, but most adults can recognize the presence of both obsessions and compulsions. Cognitive-behavioural theories have long emphasized that obsessions often lead to an increase in anxiety or sense of discomfort, and that compulsions are per formed in response to obsessions. However, some evi dence indicates that compulsive behaviour is primary and that obsessions occur as a post hoc rationali zation of these behaviours, although this theory requires fur ther study 1 . Most patients with OCD are keenly aware that their compulsive symptoms are excessive and wish that they had more control over them.
Common sets of obsessions and compulsions in patients with OCD include concerns about contamina tion together with washing or cleaning, concerns about harm to self or others together with checking, intrusive aggressive or sexual thoughts together with mental rituals, and concerns about symmetry together with ordering or counting 2, 3 (Fig. 2 ). Failing to discard items is characteristic of hoarding disorder, but hoarding to pre vent harm, for example, can also be seen in OCD. These symptom dimensions have been observed around the world, indicating that in some ways OCD is a seemingly homogenous disorder. Nevertheless, OCD can present with a range of less common symptoms, including scru pulosity, obsessional jealousy and musical obsessions [4] [5] [6] . Avoidance is another key feature of OCD; individuals might curtail a range of activities to avoid obsessions being triggered.
The major international classifications of mental dis orders, the Diagnostic and Statistical Manual of Mental Disorders (DSM) and the International Classification of Diseases (ICD), have each introduced a chapter on OCRDs 7, 8 ( Fig. 1) . Although there are important over laps between OCD and the other OCRDs, including intersecting comorbidities and family history 9, 10 , there are also key differences in their biology, assessment and Abstract | Obsessive-compulsive disorder (OCD) is a highly prevalent and chronic condition that is associated with substantial global disability. OCD is the key example of the 'obsessivecompulsive and related disorders', a group of conditions which are now classified together in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, and the International Classification of Diseases, 11th Revision, and which are often underdiagnosed and undertreated. In addition, OCD is an important example of a neuropsychiatric disorder in which rigorous research on phenomenology , psychobiology , pharmacotherapy and psychotherapy has contributed to better recognition, assessment and outcomes. Although OCD is a relatively homogenous disorder with similar symptom dimensions globally, individualized assessment of symptoms, the degree of insight, and the extent of comorbidity is needed. Several neurobiological mechanisms underlying OCD have been identified, including specific brain circuits that underpin OCD. In addition, laboratory models have demonstrated how cellular and molecular dysfunction underpins repetitive stereotyped behaviours, and the genetic architecture of OCD i s increasingly understood. Effective treatments for OCD include serotonin reuptake i n h i b i t ors a n d c o g ni tiveb e h a v i o ural t h e r a py , and neurosurgery for those with intractable symptoms. Integration of global mental health and translational neuroscience approaches could further advance knowledge on OCD and improve clinical outcomes. management 7, 8 . This Primer discusses the epidemiology and evaluation of OCD, its pathogenesis and under lying mechanisms, and its clinical management. In addi tion, this Primer discusses quality of life (QOL) issues associated with OCD and key outstanding research questions.
Epidemiology

Prevalence and demographics
OCD was initially believed to be quite rare. However, the first rigorous community surveys that used operational criteria for the diagnosis of mental disorders demon strated that OCD was one of the most prevalent mental disorders 11 , and OCD was estimated to make a consider able contribution to the global burden of disease 12 . More recent nationally representative surveys have confirmed that OCD has a lifetime prevalence of 2-3%, although figures vary across regions, and that it is associated with substantial comorbidity and morbidity 13 . Few socio demographic correlates of OCD or its symptomatology have been demonstrated in epidemiological studies 14, 15 . OCD is more common in females than in males in the community, whereas the ratio of females to males is often fairly even in clinical samples. Similarly, OCD is found in individuals across socioeconomic classes, as well as in low income, middle income and high income countries.
OCD typically starts early in life and has a long dura tion. In the National Comorbidity Survey Replication (NCS R) study, nearly a quarter of males had onset before 10 years of age 14 . In females, onset often occurs during adolescence, although OCD can be precipitated in the peripartum or postpartum period in some women 16 . Consistent with the early age of onset, the strongest sociodemographic predictor of lifetime OCD is age, with the odds of onset highest for individuals 18−29 years of age 14 . However, a few onsets do occur in individu als older than 30 years of age. Longitudinal clinical and community studies have demonstrated that OCD symp toms can persist for decades, although remission can occur in a considerable number of individuals 17 .
The clinical features of OCD are similar in patients in clinical and community studies. In a range of studies in clinical settings, obsessions and compulsions were found to fall into a small number of symptom dimensions, including concerns about contamination (with subse quent cleaning), concerns about harm (with subsequent checking) and concerns about symmetry (with subse quent ordering) 2, 3 . Similar symptom profiles in OCD have been observed in community surveys across dif ferent countries 13, 14 . Although social and cultural factors can certainly impact the expression and experience of obsessive-compulsive symptoms (for example, concerns about contamination could focus on syphilis in one region, and on HIV in another), there is also considerable uniformity of OCD symptoms across the world 18 .
Comorbidity and morbidity
OCD is characterized by substantial comorbidity. In the NCS R, 90% of respondents with lifetime OCD (based on DSM IV diagnostic criteria) met the diagnostic crite ria for another lifetime disorder in DSM IV; of these dis orders, the most common were anxiety disorders, mood disorders, impulse control disorders and substance use disorders 14 ( Fig. 3) . Tic disorders and other OCRDs also commonly co occur with OCD. In 79.2% of cases, OCD began after the comorbid anxiety disorders, whereas OCD was about equally likely to begin before or after a mood disorder, and began after comorbid impulse control and substance use disorders in 92.8% and 58.9% of cases, respectively 14 . In addition, some evidence sug gests increased comorbidity of general medical disorders in individuals with OCD 19 . OCD is often a seriously impairing disorder, with 65.3% of 12month cases (that is, individuals with OCD symptoms in the 12 months before assessment) in the NCS R reporting severe role impairment on the Sheehan Disability Scale 14 . In addition, those in the clinically severe subgroup reported the highest impairment rat ings in relationships and social functioning domains. 12month OCD was associated with an average of 45.7 days out of role in the prior 12 months. Increased mortality has also been observed in OCD 20 . Despite growing awareness of OCD and associated morbidity, this condition is underdiagnosed and undertreated; in the NCS R, only a minority of severe cases (30.9%) received treatment specifically for OCD 14 .
Limitations of epidemiological research
Important limitations of the current epidemiological evi dence for OCD should be emphasized. First, many stud ies use lay interviewer diagnoses of OCD; however, some data question the validity of this method of diagnosis and further work to determine concordance between lay and clinical interview diagnosis is needed 14, 21 . In addition, cross national data on OCD from surveys that have used similar methodologies are sparse 22 . Finally, survey interviews that are commonly used in epidemiological studies, such as the Composite International Diagnostic Interview, have not distinguished rigorously between OCD and other OCRDs (such as body dysmorphic dis order, hoarding disorder, or Tourette syndrome); thus, it is possible that some respondents with OCRDs are diagnosed with OCD, or that these disorders are entirely missed. Additional analyses from the World Mental Health Survey consortium over time could contribute to a better understanding of the prevalence and correlates of OCD across the globe 23 .
Risk factors
Twin studies have shed light on the genetic and environ mental contributors to OCD 24 . One meta analysis of twin studies suggested that additive genetic effects accounted for ~40% of the variance, and non shared environ ment accounted for ~51% of the variance in obsessivecompulsive symptoms 24 . In addition, an aetiological role of gene-environmental interactions in OCD, and the shaping of obsessive-compulsive symptoms by very gen eral aetiological factors (such as those influencing negative emotionality) have preliminary supporting evidence 24 . Some subtypes of OCD might have a higher heritability than others, including early onset OCD with tics 25 . Candidate gene studies have suggested a potential role for variants in serotonergic, catecholaminergic and glutamatergic genes in OCD 26, 27 , but these studies have been underpowered. More recent genome wide association studies have indicated that OCD is a poly genic disorder with many identified risk loci of small effect, including variants in glutamatergic genes (see Mechanisms/pathophysiology, below) 28 . Investigation of copy number variants found a 3.3fold increased bur den of large deletions that were associated with other neurodevelopmental disorders in patients with OCD 29 . Notably, half of these deletions were located in 16p13.11, and three 16p13.11 deletions were confirmed de novo. In addition, the overall de novo rate of large CNVs in OCD was 1.4%, which is midway between rates found in healthy controls and autism spectrum disorders 29 . A broad range of environmental factors, including adverse perinatal events such as birth complications, and stressful or traumatic events, have been identified as potential risk factors for OCD [30] [31] [32] . However, addi tional work is needed to assess the relationship between the environome and OCD. In addition, more research is required to carefully delineate the cellular and molecu lar pathways by which genetic and environmental risk factors influence endophenotypes, and ultimately OCD. Such work, including additional genetic imaging studies and genome wide environmental interaction studies, is needed if a precision or personalized medicine approach is to be developed for the prevention and management of OCD 33 .
Mechanisms/pathophysiology
Cognitive-affective dysfunction Studies in the mid20th century demonstrating that ani mals could be deconditioned to fear gave rise to clinical research on behavioural therapies, including exposure and response prevention (ERP) for OCD 34, 35 . In turn, clinical findings gave impetus to the development of behavioural and cognitive-behavioural models of OCD, with subsequent work suggesting that obsessions can Fig. 2 | OCD symptom dimensions. Studies using a factor-analytic approach have consistently supported a four-factor or five-factor model of obsessive-compulsive disorder (OCD) symptoms, including a 'contamination' dimension (contamination or cleanliness obsessions and cleaning compulsions), a 'harmful thoughts' dimension (thoughts of harm to self and others and checking compulsions), a 'forbidden thoughts' dimension (aggressive, sexual, religious obsessions with mental rituals or praying), a 'symmetry' factor (symmetry obsessions, and repeating, ordering and counting compulsions), and a 'hoarding' factor (hoarding or saving obsessions and related compulsions) 2, 3 . Hoarding disorder is considered as a separate entity in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, although hoarding symptoms can also be found in patients with OCD in some cases.
be conceptualized as a noxious stimuli to which indi viduals fail to habituate 36 , that negative interpretations of obsessive thoughts lead to a range of neutralizing behaviours (that is, compulsions) which serve to main tain these interpretations and the obsessive thoughts 37 , and that there are deficits in mechanisms that are central to extinction learning 38 . Such models in turn provide a foundation for fear habituation (emphasized in behav ioural therapy), belief disconfirmation (emphasized in cognitive therapy), and exposure optimization tech niques (to address deficits in extinction learning) 38, 39 . Expert consensus has suggested that key belief domains or meta cognitions in OCD include the overestimation of threat and excessive concern about the importance of controlling one's thoughts 40 . Similarly, cognitive-affective research paradigms have emphasized dysfunctions in processes that might lead to increased concerns about harm (for example, increased sensitivity to disgust evoking stimuli and excessive performance monitoring), or that might lead to an inability to control responses to such concerns (for example, impairment in executive functions such as response inhibition and excessive stimulus-response habit formation) 41 . Indeed, a range of impairments in patients with OCD have been observed in neuro psychological studies, including altered executive function (such as altered cognitive flexibility, planning, working memory and response inhibition), and alter ations in disgust processing, fear extinction, reward pro cessing and emotion regulation, among others, have been reported in affective studies 42 . However, further work is needed to determine how these cognitive affective alterations contribute to the symptoms of OCD 43 . Furthermore, although such research has been useful in conceptualizing and researching OCD, cognitiveaffective alterations are not yet sufficiently sensitive or specific to usefully guide clinical practice for OCD.
Neural circuits
The defects in cognitive and affective processing in patients with OCD could be mediated by alterations in specific neural circuits. Early work established that OCD could emerge in individuals with specific neural lesions (Box 1). Although data from studies using animal models of stereotyped behaviours and grooming have con tributed to understanding the neural circuitry of OCD 44, 45 , advances in functional and structural brain imaging methods have been particularly important in advancing the field and have given impetus to influential models of OCD neurocircuitry. Such models have integrated data from neuroimaging and cognitive-affective studies by hypothesizing the involvement of parallel, partly segre gated, cortico-striato-thalamo-cortical (CSTC) circuits that are involved in sensorimotor, cognitive, affective and motivational processes in OCD 46, 47 (Fig. 4) . Indeed, data from functional and structural imaging studies support this hypothesis by demonstrating alterations in several brain regions that comprise these circuits in patients with OCD compared with healthy individuals. Other models have also implicated alterations in frontolimbic, frontoparietal and cerebellar networks 48, 49 .
Functional alterations. The first functional brain imaging studies in OCD used PET and functional MRI (fMRI) to observe changes in brain activation on symptom provocation using disorder relevant tactile and visual stimuli (often these stimuli were related to contamination fears) 47, 48 . An early meta analysis using 50 . A more recent meta analysis using signal differential map ping demonstrated increased activation in the bilateral amygdala, right putamen, orbitofrontal cortex extending into the anterior cingulate and ventromedial prefrontal cortex, middle temporal cortex, and the left inferior occipital cortex during emotional processing (induced, for example, by exposure to disease relevant stimuli), particularly in OCD 51 . Of these changes, alterations in the amygdala were most pronounced in unmedicated patients, and those in the right putamen were most prominent in medicated patients.
Other functional imaging studies have investigated brain activation while performing tasks that rely on executive functions, such as working memory, response inhibition, reversal learning and planning 48, 49 . Although a number of consistent findings have emerged from these studies, variations in study design, task condition contrasts, and task load, combined with modest sample sizes and lack of control for multiple comparisons, have likely contributed to inconsistencies in the literature. In general, altered frontostriatal and frontoparietal recruit ment has been found in these studies, but the extent of hyperactivation or hypoactivation is thought to depend on the participants' capacity to recruit neural circuits to compensate for network inefficiency (which could cause hyperactivation), and on interference with neural circuit recruitment due to limbic activity (which might lead to hypoactivation). Some of the changes reported in patients with OCD are also found in unaffected siblings, suggesting that genetic factors could contribute to these network alterations 48, 49 . Meta analyses have been useful in summarizing studies evaluating executive function in patients with OCD. Decreased task relevant activation in the caudate nucleus, putamen, cingulate cortex and prefrontal regions were reported in one meta analysis of 28 fMRI studies of executive function 52 , whereas frontostriatal abnormalities and parietal and cerebellar involvement were reported in another meta analysis of studies of executive function 53 . More recent studies have focused on the balance between habitual and goal directed behaviour, and have demonstrated increased habit formation in patients with OCD compared with healthy controls which is associ ated with hyperactivation of the caudate nucleus 54 . One meta analysis that combined 54 fMRI studies on both cognitive and affective paradigms in OCD demonstrated differences in brain activation across these paradigms 55 . During emotional processing (an affective paradigm), patients with OCD had overactivation of brain networks involved in salience, arousal and habitual responding, such as the anterior cingulate cortex, insula, head of the caudate nucleus and putamen, and underactivation of regions that have been implicated in cognitive con trol, such as the medial prefrontal cortex and posterior caudate, compared with healthy controls 55 . In addition, during cognitive paradigms, patients with OCD had increased activation in regions involved in self referential processing, such as the precuneus and the posterior cin gulate cortex, and decreased activation in subcortical regions involved in goal directed behaviour and motor control, such as the pallidum, ventral anterior thalamus and posterior part of the caudate nucleus 55 . The pattern of alterations in this study is consistent with increased habitual responding and affective processing, and impaired cognitive control in patients with OCD. The exact involvement of various neural circuits likely varies with age and disease stage, and is dependent on symptom characteristics, disease chronicity, and neurocognitive profile (Fig. 5) .
Cognitive-affective dysfunctions such as alterations in emotional processing and cognitive control could lack specificity for particular disorders and cut across diagnos tic entities [56] [57] [58] . The majority of brain imaging studies of OCD compare patients with OCD with healthy controls, without an additional clinical control group consisting of patients with related disorders, except for some stud ies that have compared patients with OCD with patients with autism spectrum disorder during decision making 59 , patients with attention deficit/hyperactivity disorder during temporal discounting (a measure of impulsiv ity) 60 , and patients with panic disorder and hypochon driasis during attention bias and planning 48, 49 . Conversely, impairments in inhibitory control could be associated with different network abnormalities in OCD, attention deficit/hyperactivity disorder, and Tourette syndrome 61, 62 .
Structural alterations. The development of automated brain imaging analysis techniques, such as voxel based morphometry (VBM), has facilitated systematic inves tigation of whole brain morphometry and has increased the reliability and reproducibility of results. Regional brain volume reflects a combination of grey matter thick ness, cortical surface area and cortical folding; cortical surface and folding measurements might be indicative of prenatal neurodevelopmental processes, whereas corti cal thickness changes dynamically across the lifespan as a consequence of development and disease.
Box 1 | Neurological insults and OCD
Certain neurological lesions can cause obsessive-compulsive disorder (OCD). For example, after the influenza epidemic in the first part of the 20th century, obsessive-compulsive symptoms were noted in patients with encephalitis lethargica and basal ganglia lesions 199 . In addition, subsequent research has identified obsessivecompulsive symptoms in patients with neurological conditions that affect the basal ganglia, including Sydenham chorea and neuroacanthocytosis 200 . OCD can also be a sequela of neurological lesions that affect other areas, such as the frontal lobe, suggesting that frontostriatal circuitry could play a role in OCD pathogenesis 201 . Some of the most interesting literature at the intersection of OCD and neurology is that describing obsessive-compulsive symptoms that are precipitated by streptococcal infection -so-called paediatric autoimmune neuropsychiatric disorders associated with Streptococcus (PANDAS) 202 . The recognition of PANDAS was given impetus by early work that demonstrated the presence of obsessive-compulsive symptoms in Sydenham chorea (which is caused by childhood streptococcal infection) 203 and, later, in individuals with rheumatic fever 204 . Advances have been made in formulating diagnostic criteria for PANDAS, in investigating the relevant autoimmune mechanisms, and in developing specific treatments for this disorder 205, 206 . However, research has shifted from PANDAS to a broader disorder -paediatric acute-onset neuropsychiatric syndrome -which is characterized by the sudden onset of obsessive-compulsive symptoms that can occur in response to a range of infections and other insults 205, 206 .
Smaller dorsomedial prefrontal, medial orbitofron tal and insular opercular volumes, and larger volumes of the putamen and cerebellum (of which the larger putamen was most pronounced in older patients) was reported in one of the first VBM studies in OCD 63 . This study also demonstrated that the patients with promi nent symptoms of aggressive obsessions and checking compulsions had a smaller volume of the right amygdala compared with other individuals with OCD, suggesting that different symptom dimensions might be under pinned by different neural mechanisms. In accordance with these data, other studies have also reported evi dence of symptom dimension specific profiles, with harm related symptoms associated with a decreased volume of bilateral anterior temporal poles, and con tamination symptoms associated with a smaller caudate nucleus 64 . Although such work is important in proposing hypotheses about the neural circuitry of OCD, rela tively small sample sizes can lead to false positive and false negative findings. Meta analysis may be useful in synthesizing findings from different studies. The first meta analysis of brain structure in OCD used signal differential mapping of 12 VBM studies and reported a decreased volume of the dorsomedial prefrontal cortex and an increased volume of the bilateral lenticular nuclei (part of the striatum), consistent with a frontostriatal model of OCD 65 . This decreased dorsomedial prefrontal volume was not specific for OCD and was also observed in other anxiety disorders, whereas the increased volume of the striatum was specific for OCD, with patients with other anxiety disorders showing decreased lenticular volume 66 . A consortium of international sites subsequently undertook a mega analysis of pooled VBM data from adults with OCD and matched healthy controls (n = 780).
This study reported smaller volumes of the dorso medial prefrontal cortex and the bilateral insular oper cular region, and increased volume of the cerebellum in patients with OCD 67 . In line with an earlier study, age related effects were observed in striatal and limbic regions, with preservation of putamen volume and more pronounced age related volume decreases in limbic parts of the middle and inferior temporal cortex with increasing age. Most of these findings were replicated using a different analysis technique focusing on cortical thickness 68 . In addition, altered structured covariance between the ventral striatum and insular operculum region was observed predominantly in older patients 69 .
Together, these findings suggest that neuroplastic changes occur in patients with OCD, which could occur as a result of disease chronicity and/or long term effects of medication.
Studies from the ENIGMA OCD working group aimed to further evaluate changes in neuroanatom ical structures associated with OCD over time 70 , and demonstrated a decreased volume of the hippocampus and an increased volume of the bilateral putamen in adults with OCD, compared with healthy controls 71 ; both changes were more pronounced in medicated patients. In this study, reductions in hippocampus volume were more pronounced in those with comorbid depression, consistent with evidence that hippo campal changes are found in many disorders 72 . In addition, an increased volume of the pallidum was mainly present in the adults with OCD who had childonset disease, suggesting that the striatal volumetric chan ges are a result of disease chronicity and treatment. In children with OCD, a larger volume of the thalamus was found in unmedicated individuals com pared with healthy controls. In addition, medicated patients with OCD had thinner cortex in frontal, temporal, parietal, temporal and occipital regions (adult sample) and smaller surface areas in frontal regions (paediatric sample), whereas unmedicated patients with OCD did not differ from controls 73 . Changes in brain white matter have also been reported in patients with OCD. Indeed, widespread white matter abnormalities were reported in one meta analysis, particularly in the anterior midline tracts (crossing between the anterior parts of cingulum bundle and the body of corpus callosum), and in samples with a higher proportion of medicated patients 74 . In addition, overlapping white matter abnormalities were observed across several affective disorders, including depression, bipolar disorder, OCD, post traumatic stress disorder and social anxiety disorder, with decreased fractional anistropy in frontotemporal and frontoparietal regions, and the most robust and replicable finding in the superior longitudinal fasciculus 75 .
Summary. In summary, some neurobiological alter ations in OCD are common with other psychiatric dis orders (such as smaller hippocampus, dorsomedial prefrontal cortex and insular opercular region), whereas others are more specific for OCD (such as larger volume of the basal ganglia, which is most pronounced in older patients and likely related to disease chronicity and/or long term effects of medication). A larger thalamus in unmedicated children with OCD may reflect altered brain maturation. There is a need for long itudinal studies of OCD and OCRDs with a specific focus on neurodevelopment before onset of the dis order, as well as the long term effects of pharmacotherapy and other interventions. Advances in highresolution MRI and improved segmentation of the subregions of the striatum and thalamus may also be useful in delineating the precise neural circuitry in patients with OCD.
Molecular mechanisms
Several key neurotransmitter systems are found within CSTC circuits, including serotonin, dopamine and glutamate, and these might have an important role in underpinning OCD symptoms. The early finding that OCD responds selectively to serotonin reuptake inhibi tors (SRIs) has led to substantial attention on the sero tonergic system. The involvement of the dopaminergic The involvement of the circuits is hypothesized to depend on the symptom profile and the disease stage. In early phases of obsessive-compulsive disorder (OCD), alterations within the dorsal cognitive, ventral cognitive and ventral reward cortico-striato-thalamo-cortical (CSTC) circuits and the frontolimbic circuit are hypothesized to be related to symptoms involving anxiety , uncertainty , and goal-directed behaviours. In later phases of OCD, alterations within the sensorimotor, dorsal cognitive and ventral cognitive CSTC circuits are hypothesized to be related to symptoms involving habitual behaviours. dCaud, dorsal part of caudate nucleus; dlPFC, dorsolateral prefrontal cortex; dmPFC, dorsomedial prefrontal cortex; IFG, inferior frontal gyrus; NAcc, nucleus accumbens; OFC, orbitofrontal cortex; pPut, posterior part of putamen; pre-SMA , pre-supplementary motor area; SMA , supplementary motor area; Tham, Thalamus; vCaud, ventral part of caudate nucleus; vlPFC, ventrolateral prefrontal cortex; vmPFC, ventromedial prefrontal cortex. Adapted with permission from reF.
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system was highlighted after patients responded to aug mentation of SRIs with dopamine D2 receptor antag onists, among other data, whereas more recent studies have focused on the glutamatergic system. Although the selective efficacy of the SRIs in patients with OCD gave significant impetus to a serotonin hypothesis, there is surprisingly little evidence of an underlying serotonin deficit that has a primary causal role in OCD 76 . Alterations in levels of serotonin and its metabolites in the cerebrospinal fluid of patients with OCD, with normalization after successful treatment, have been reported in some studies, although evidence is sparse 76 . In addition, associations between variants in serotonergic genes (such as the serotonin transporter) and OCD have been reported in a few studies 26, 27 , and altered serotonin transporter receptor binding in areas such as the midbrain has been observed in some studies, although not all data are consistent 77, 78 . Dopamine has a key role in stereotypic behaviour, including grooming, in animal models 45 . In addition, dopamine has an important role in a range of cognitive and affective processes including reward processing, which could be altered in OCD. Strong evidence suggests a central role of the dopaminergic system in Tourette syndrome, which many would consider to be one of the key OCRDs 79 . Supporting the role of dopamine in OCD, some studies have reported an association between vari ants in catecholaminergic genes (including COMT) and OCD 26, 27 , and molecular imaging studies have sug gested alterations in specific dopaminergic receptors, such as a decrease in striatal dopamine D2 receptors, in OCD 78, 80 . Finally, as discussed below, there might be some therapeutic role for dopamine D2 receptor blockers in OCD 81 . Glutamatergic neurons originating in the prefrontal cortex have a key role in CSTC circuitry, with these neurons projecting to the striatum. Cerebrospinal fluid and magnetic resonance spectroscopy studies have indicated alterations in glutamatergic metabolites, confirming that this system might have a role in OCD, although not all findings are consistent 82, 83 . In addi tion, variants in gluta matergic genes (such as SLC1A1 and GRIN2B) are associated with OCD 84 , and meta analysis of genome wide association studies in OCD have implicated several glutamatergic system genes (such as GRID2 and DLGAP1) 28 . A different mem ber of the DLGAP family, DLGAP3 (or SAPAP3), is expressed in the striatum and has a key role in a mouse model of OCD, whereby mice with deletion of SAPAP3 have defects in corticostriatal synapses and compulsive grooming behaviour that is decreased by a selective SRI (SSRI) 85 . Although no gluta matergic agent has been registered for the treatment of OCD yet, several have now been studied in randomized controlled trials with promising results 86 . Other neurotransmitters and neuropeptides have been implicated in OCD 76 . The involvement of inflamma tory and immune pathways in common mental dis orders is increasingly apparent, although findings in OCD remain preliminary 83, 87, 88 . Molecular studies could ulti mately also allow delineation of pathways from genetic and environmental risk factors, through to alterations in brain imaging and other possible endophenotypes, and to different stages and subtypes of OCD 89 .
Diagnosis, screening and prevention Diagnostic criteria Both DSM5 and ICD11 diagnostic criteria for OCD emphasize that OCD is characterized by the presence of obsessions and/or compulsions 8, 25 . In addition, the diag nostic criteria for OCD include a clinical significance criterion and a diagnostic hierarchy criterion (Box 2). The clinical criterion states that a diagnosis of OCD requires obsessions and compulsions that are associated with clinically significant distress or functional impairment, Box 2 | DSM-5 diagnostic criteria for OCD 207 The presence of obsessions, compulsions, or both: • Obsessions are defined by the following:
-Recurrent and persistent thoughts, urges, or impulses that are experienced, at some time during the disturbance, as intrusive and unwanted, and that in most individuals cause marked anxiety or distress. -The individual attempts to ignore or suppress such thoughts, urges, or images, or to neutralize them with some other thought or action (that is, by performing a compulsion).
• Compulsions are defined by the following:
-Repetitive behaviours (for example, hand washing, ordering or checking) or mental acts (for example, praying, counting or repeating words silently) that the individual feels driven to perform in response to an obsession or according to rules that must be applied rigidly. -The behaviours or mental acts a are aimed at preventing or reducing anxiety or distress, or preventing some dreaded event or situation; however, these behaviours or mental acts are not connected in a realistic way with what they are designed to neutralize or prevent, or are clearly excessive.
The obsessions or compulsions are time-consuming (for example take >1 hour per day) or cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.
The obsessive-compulsive symptoms are not attributable to the physiological effects of a substance (for example, a drug of abuse or a medication) or another medical condition.
The disturbance is not better explained by the symptoms of another mental disorder (for example: excessive worries, as in generalized anxiety disorder; preoccupation with appearance, as in body dysmorphic disorder; difficulty discarding or parting with possessions, as in hoarding disorder; hair pulling, as in trichotillomania (hair-pulling disorder); skin picking, as in excoriation (skin-picking) disorder; stereotypies, as in stereotypic movement disorder; ritualized eating behaviour, as in eating disorders; preoccupation with substances or gambling, as in substance-related and addictive disorders; preoccupation with having an illness, as in illness anxiety disorder; sexual urges or fantasies, as in paraphilic disorders; impulses, as in disruptive, impulsecontrol, and conduct disorders; guilty ruminations, as in major depressive disorder; thought insertion or delusional preoccupations, as in schizophrenia spectrum and other psychotic disorders; or repetitive patterns of behaviour, as in autism spectrum disorder). which is important given that intrusive thoughts and repetitive behaviours are common, and that rituals are a normal part of development. The diagnostic hierarchy criterion states that the obsessions and compul sions are neither a manifestation of another mental disorder, nor are they attributable to the physiological effects of a substance (such as a drug of abuse or a medication) or another medical condition. As previously mentioned, obsessions and compulsions in patients with OCD fall into a small number of symptom dimensions (Fig. 2) . Within a particular individual, obsessions and com pulsions tend to be stable, with any changes occurring within symptom dimensions 90 . Studies evaluating sex differences in symptom dimensions have not reported consistent differences 91, 92 . A range of specifiers and subtypes of OCD have been proposed 25 . The DSM and ICD chapters on OCRDs include specifiers for some of these conditions (Box 2), such as insight specifiers, which refer to the degree of insight displayed by patients. Three insight specifiers are included in the DSM5: with good or fair insight, with poor insight, and with absent insight or delusional beliefs. Individuals with OCD and absent insight or delu sional beliefs are convinced that their OCD beliefs are true; it is important that this subtype of OCD is recog nized and appropriately diagnosed and treated, rather than erroneously diagnosed as a psychotic disorder and inappropriately treated. In addition, the DSM5 includes a tic specifier that denotes individuals with a current or past tic disorder; this specifier reflects the growing evidence that patients with OCD with or without tics differ in key aspects of phenomenology and psycho biology, and that the evaluation and management of these patients should be tailored accordingly 25 . In addi tion, this specifier is relevant for appreciating the close relationship between OCD and Tourette syndrome. Males are more likely to have early onset OCD (that starts before puberty), as well as comorbid tics 91, 92 . Other subtypes of OCD, including early onset OCD and paedi atric autoimmune neuropsychiatric disorders associ ated with Streptococcus (PANDAS; Box 1) have also been investigated by researchers 25 .
Differential diagnosis
OCD should be differentiated from normal health, as well as from a number of other psychiatric conditions. In general, this is typically carried out by a general psychiatric assessment. Intrusive thoughts and repet itive behaviours are common in the general popula tion (such as thoughts of harming oneself or others and double checking locks), but a diagnosis of OCD should be made only if these thoughts and behaviours are time consuming (such as taking up more than 1 hour a day) and cause substantial distress or functional impairment. Recurrent thoughts and rituals also occur in a range of OCRDs (such as body dysmorphic disorder, hoarding disorder, trichotillomania and excoriation disorder), somatic symptom disorders (for example, illness anxiety disorder) and eating disorders (such as anorexia nervosa), but in all of these conditions the foci of apprehension and the form of repetitive behaviours are distinct from OCD.
Worries and ruminations that are characteristic of generalized anxiety disorder and depression are typically about real life concerns and tend to be less irrational and ego dystonic than in OCD. Compulsions are also not typically seen under these conditions. Substance related and addictive disorders, as well as the paraphilic disorders, disruptive, impulsive control and conduct dis orders, often have an ego syntonic, gratifying component, particularly in the short term. Patients with OCD and poor or absent insight have beliefs that are OCD related, without the additional features of the schizophrenia spectrum and other psychotic disorders, such as thought disorder and hallucinations. Obsessions and compul sions can be difficult to distinguish from the restricted, repetitive, and inflexible activities and interests that are typical of autism spectrum disorders; however, patients with OCD generally do not present with difficulties in social communication or reciprocal social interactions that are typical of autism spectrum disorders.
Assessment
A comprehensive assessment is a first critical step in the diagnosis and management of OCD. The goals of this assessment include making an accurate diagnosis, gain ing information on presenting obsessive-compulsive symptoms, determining symptom severity, and assisting with selection of relevant treatment targets. The core of this assessment is taking a detailed psychiatric history and examining the mental status. In addition, a number of well studied assessment measures with good psycho metric properties can be useful for assisting with the diagnosis of OCD, for the identification of symptoms, the measurement of symptom severity, and monitoring of treatment response 93 . Structured diagnostic interviews for diagnosing OCD include the Structured Clinical Interview for DSM5 (SCID5 Clinician or Research version) for adults and the Anxiety Disorders Interview Schedule for DSM5 (ADIS5), which includes both an adult and a child or parent version. The Mini International Neuropsychiatric Interview (MINI version 7.0) is a shorter instrument, has also been revised in accordance with DSM5, and is available for use in adults and children or adolescents. A Structured Clinical Interview for OCRDs could be useful in assessing common comorbidities 94 . A number of standardized symptom severity meas ures are available; of these, the Yale Brown ObsessiveCompulsive Scale (Y BOCS) and the Children's Y BOC (CY BOCS) are widely used, comprise a symptom checklist and a severity scale, and are available in self report format 95 . The Dimensional Yale Brown Obsessive-Compulsive Scale (DY BOCS) allows more detailed assessment of OCD symptom dimensions and their severity 96 . By contrast, the shorter Florida Obsessive-Compulsive Inventory (FOCI) comprises a symptom checklist of common obsessive-compulsive symptoms and only five items to assess symptom sever ity and impairment 97 . The FOCI has been adapted to address other OCRDs, and is included as a dimensional rating scale in the DSM5. A range of other measures might be useful for the assessment and monitoring of OCD, including scales that are focused on sensory phenomena, insight, or measures of family accom modation to obsessive-compulsive symptoms (that is, family behaviour that facilitates rather than challenges OCD symptoms -for example, providing reassur ance in response to obsessive doubts, assisting the patient with avoidance behaviours, and participating in rituals) 93, [98] [99] [100] .
Prevention
Despite growing attention to the prevention of, and early intervention in, mental disorders, relatively lit tle attention has been paid to such issues in OCD 101 . Targets for OCD primary prevention could potentially include psychoeducation and the reduction of family accommodation in high risk individuals with subclin ical or no symptoms, whereas secondary prevention could include the early identification and management of clinical OCD 102 . Further work is needed to empha size the different stages of OCD (ranging from at risk or prodromal illness to chronic or refractory illness) and to gather data on preventive and early intervention strategies 102 .
Management
Treatment of OCD comprises several components, start ing with building a therapeutic alliance with the patient and psychoeducation, followed by psychological and/or pharmacological approaches, and, for patients with treatment resistant OCD, neuromodulation and neuro surgery (Fig. 6) . Alternative interventions have also attracted interest but require more evidence 103 . Although general principles of management exist, they need to be individually tailored. Thus, for example, some comor bid conditions (such as depression) respond to first line OCD pharmacotherapies, whereas others (such as bipolar disorder) might require additional inter ventions 104 . Although similar pharmacotherapies and psycho therapies are used throughout the lifespan [105] [106] [107] , key modifications are needed when treating children and adolescents; however, a comprehensive discussion is beyond the scope of this Primer 107 .
Psychoeducation
Patients and their family members can experience con siderable relief when they are told by a professional that they have a relatively common disorder which is increas ingly well understood, and that the available treatments bring at least partial symptom reduction and improved QOL. Factors such as stigma, prejudice, and the role of the family and significant others in aggravating or main taining OCD (such as family accommodation) should be addressed, so that all involved can contribute to treat ment success. For this reason, treatment should include the family whenever possible (and particularly in the case of children or adolescents with OCD).
Substantial delays can occur before patients with OCD seek treatment. Possible reasons for this delay include a lack of knowledge about the disorder, embar rassment about their symptoms, or anxiety about expo sure to feared stimuli. Such challenges to engaging with and adhering to treatment can be aggravated in patients with poor insight, and it has been suggested that motivational interviewing techniques can be help ful in such individuals 108, 109 . These techniques focus on empathizing with the patient's experience, discussing the benefits of symptoms as well as their costs, and exploring the benefits and costs of symptom reduction. Building a therapeutic alliance is key, as is working with consumer advocacy organizations to decrease stigmatization and to improve health literacy. Fortunately, several such organi zations are now available, such as the International OCD Foundation, OCD Action, the South African Depression and Anxiety Group and Astoc St.
Psychotherapy
Cognitive-behavioural therapy (CBT) is the most evidence based form of psychotherapy for OCD (Fig. 6) . Indeed, meta analyses of randomized controlled trials have consistently demonstrated that CBT significantly improves OCD symptoms in both adults and chil dren 110, 111 . CBT comprises two components: cognitive reappraisal and behavioural intervention. The latter, specifically ERP, is the psychological treatment of choice for OCD. ERP involves gradual and prolonged exposure to fear provoking stimuli combined with instructions to abstain from the compulsive behaviour. The integration of ERP with cognitive components, such as the discus sion of feared consequences and dysfunctional beliefs, can make ERP less aversive and enhance its effective ness 112 , particularly for patients with poor insight and for those who are less tolerant to exposure 113 . Individual and group CBT (that is, ERP with cog nitive reappraisal), delivered in person or by internet based protocols, are effective for the treatment of OCD 114, 115 . The most robust predictor of good short term and long term outcome with CBT is patient adherence to between session homework, such as carrying out ERP exercises in the home environment 116 . CBT can be used as the initial treatment for OCD, particularly if this is the patient's preferred treatment option, if there is access to trained clinicians, and in the absence of comorbid con ditions that might require pharmacotherapy 113 . Meta analyses of randomized controlled trials have indicated that CBT has larger effect sizes than pharmacological therapy for the treatment of OCD. Indeed, one recent review, for example, indicated a number needed to treat of 3 for CBT and 5 for SSRIs as a measure of treatment efficacy 113 . However, such findings do not fully take into account the presence of comorbidities (which can lead to the exclusion of patients with more severe OCD from CBT trials), the baseline severity of OCD (such as the presence of poor insight, poor functioning or personality traits related to the ability to change), the placebo effect observed in pharmacotherapy trials (which is likely greater than the effect seen in the control arm of CBT studies), and the fact that many CBT trials have included patients who are taking stable doses of SSRIs 113, 117, 118 . Protocols of intensive CBT (multiple sessions over a few days, often in an inpatient setting) for OCD have been tested not only for severe, treatment resistant patients, but also as a first line treatment 119 . Although the number of such trials is still small, the initial findings of intensive approaches suggest that further work in this area might be useful.
Pharmacotherapy
Pharmacotherapy might also be used to initiate treat ment of OCD. SSRIs are the first line pharmacological treatment for OCD based on their evidence of efficacy, tolerability, safety and absence of abuse potential 120 . As a rule, higher doses of SSRIs are used for OCD than for other anxiety disorders or major depression; higher doses of SSRIs are associated with greater treatment efficacy, but also with higher rates of dropout owing to adverse effects (such as initial gastrointestinal symptoms and sexual dysfunction) 121 . Thus, a careful assessment of SSRI adverse effects is crucial when establishing the best dose for each patient. The effect sizes of SSRIs were similar in systematic reviews 120, 122 ; however, their adverse effects differ and should be taken into account in the choice of a specific SSRI. Other characteristics to consider when choosing between different SSRIs include past treatment response, potential adverse events and drug interactions, presence of comorbid medical conditions, and cost and availability of medication 123 . Clomipramine, a non selective SRI 124 , was the first agent to show efficacy in OCD 125 . Meta analyses have suggested that clomipramine is more efficacious than SSRIs 113 . However, there are reasons to be sceptical of this finding; for example, clomipramine trials were conducted earlier on fewer treatment resistant patients with OCD, and head tohead trials directly compar ing clomipramine with SSRIs indicate equivalent effi cacy [126] [127] [128] . SSRIs have a higher safety and tolerability profile compared with clomipramine, which has advan tages for long term treatment, supporting their use as firstline agents.
OCD treatment guidelines indicate that 8-12 weeks is the optimal duration of an SSRI trial to determine effi cacy 120, 123, 129 . However, in two recent meta analyses, a sig nificant improvement in OCD symptoms was observed within the first 2 weeks of treatment with SSRIs, with the greatest incremental gains occurring early in the course of treatment 130, 131 .
Similarly, an open label trial of fluoxe tine in treatment naive patients indicated that early reduction (such as by 4 weeks) of OCD severity was the best predictor of treatment response at 12 weeks 132 . The recommended maintenance duration of pharmaco therapy is a minimum of 12-24 months after achieving remission 133 , but longer treatment might be necessary in many patients owing to the risk of relapse after discontinuing medication 134 .
Treatment resistance
Approximately half of patients with OCD who are treated with a first line treatment fail to fully respond 135, 136 . This proportion can be even higher in real world or prag matic clinical trials 137 . Several clinical predictors that are associated with a poor response have been iden tified (Box 3). Augmentation options for patients with treatment resistant OCD are outlined in Supplementary  Table 1 .
Insufficient response after CBT or SSRI monother apy can also be addressed by combinatorial therapy 46 . In one trial, effect sizes were larger with the augmentation of SSRIs with CBT, compared with augmentation with risperidone (an antipsychotic) 138 . Nevertheless, the combination of SSRIs with CBT is not always feasible, either because CBT is not available 139 or owing to dif ficulty in tolerating exposure 140 . Valid pharmacological strategies include switching to a different SSRI, using a higher dose of a SSRI than the maximum recommended dose, or a trial of a serotonin-noradrenaline reuptake inhibitor [141] [142] [143] [144] [145] [146] [147] [148] . Evidence based pharmacological SSRI augmenta tion strategies include the use of antipsychotics, clomi pramine (a tricyclic antidepressant), and glutamatergic agents [149] [150] [151] [152] [153] . In the only double blind, randomized con trolled trial that compared three pharmacological strat egies in patients with SSRI resistant OCD, fluoxetine plus placebo and fluoxetine plus clomipramine signi ficantly reduced the severity of OCD and were both significantly superior to fluoxetine plus quetiapine (an antipsychotic) 152 . Of note, the effect of time spent on fluoxetine monotherapy (6 months) was the most impor tant factor associated with the response at the endpoint. The greatest concern associated with clomipramine and SSRI combinatorial therapy is the increment in the blood levels of both drugs, which can increase the risk of severe and potentially life threatening events such as seizures, heart arrhythmia and serotonergic syndrome 154 . The augmentation of SSRIs with antipsychotics is one of the most commonly used pharmacological strategies for patients with SSRI resistant OCD 149, 150 . Indeed, one meta analysis provides evidence of efficacy for both ris peridone and aripiprazole augmentation 150 . Although other antipsychotics might also be useful, additional studies are needed. However, SSRIs have a moderate effect size in OCD and subsequent antipsychotic aug mentation has a smaller effect size, with only one third of patients with SSRI resistant OCD showing a clinically meaningful response 149 . Thus, ongoing monitoring of the risk-benefit ratio is needed in patients receiving antipsychotic augmentation of SSRIs, with particular attention on adverse events such as weight gain and metabolic dysregulation 155 . More recently, glutamatergic medications, such as N acetylcysteine, memantine, lamotrigine, topiramate, riluzole and ketamine, have been evaluated as augmen tation agents in patients with treatment resistant OCD and have demonstrated some evidence of efficacy [156] [157] [158] . Of these, N acetylcysteine augmentation has the largest evidence base -three out of five randomized controlled trials demonstrated its superiority to placebo in redu cing OCD symptoms [158] [159] [160] [161] [162] . Memantine augmentation can also be considered in clinical practice, as several trials have demonstrated its efficacy in SSRI augmentation for patients with treatment resistant OCD 163 .
Neuromodulation and neurosurgery
Neuromodulation for OCD includes both noninvasive and invasive approaches, including transcranial direct current stimulation (tDCS), repetitive transcranial mag netic stimulation (rTMS) and deep brain stimulation (DBS) (Fig. 7) . Ablative procedures have also been used in OCD. Although neuromodulation for OCD has primar ily been confined to a research context, the US FDA has tDCS involves the application of a weak current to the scalp, with only a fraction of the current entering the brain 164 . Most studies of tDCS in OCD are open label or case reports, using a range of electrode montages, targeting areas including the supplementary motor cor tex and the dorsolateral prefrontal cortex. Initial results from these studies show promise and provide impetus for further research 164, 165 . rTMS is a noninvasive technique that modulates neuro nal activity via electric currents that are induced by a magnetic coil positioned over the head 166 . rTMS has grow ing evidence of efficacy for OCD, with targets including the supplementary motor cortex and the dorsolateral prefrontal cortex 165, 167, 168 . Notably, in the pivotal trial of deep rTMS targeting the medial prefrontal cortex and anterior cingulate cortex, tailored symptom provocation was used in each session to personalize the treatment.
DBS involves the neurosurgical implantation of an electrode that can activate neighbouring neural cir cuitry 169 . This approach is reserved for very intractable cases (less than 1% of treatment seeking individuals) 170 (Box 4). Most studies of DBS target striatal areas, including the anterior limb of the internal capsule, the ventral cap sule and ventral striatum, the nucleus accumbens or the ventral caudate nucleus, the subthalamic nucleus, and the inferior thalamic peduncle 171 . Approximately 30-50% of patients with severe refractory OCD respond to these different treatments 171, 172 . Preliminary work points also to the potential of nonstriatal targets, such as the superolateral branch of the medial forebrain bundle 173 . Ablative neurosurgery for OCD has targeted several different brain structures, such as the internal capsule, anterior cingulate cortex and subcaudate white matter, with techniques respectively termed capsulotomy, ante rior cingulotomy, and subcaudate tractotomy (limbic leucotomy is a combination of the two last procedures).
Ablative methods encompass radiofrequency and radio surgical ablation, as well as the experimental technique of magnetic resonance guided focused ultrasono graphy [174] [175] [176] . Approximately 30-60% of patients with intractable OCD can achieve a significant reduction in OCD symptoms after surgery. However, only one method, gamma ventral capsulotomy, has been studied in a double blind, sham controlled randomized trial 177 . Using the criterion of response (a 35% reduction in base line Y BOCS score plus a Clinical Global Impression change score of 1 or 2), the primary outcome measure did not reach statistical significance 12 months later, although the YBOCS score reduction over that same followup period was significantly higher in the active treatment group. At the end of the followup period (54 months), 7 of 12 (58%) patients who underwent radiosurgery were responders.
Alternative treatments
A range of alternative treatments have been suggested for OCD 103 . These include yogic meditation techniques 178 , mindfulness based CBT 179, 180 , physical exercise 181, 182 and acupuncture 183 . However, further data are needed before these treatments can be routinely recommended as evidence based interventions.
Quality of life OCD is associated with considerable comorbidity and morbidity, in addition to significantly reduced QOL, in both adults and children [184] [185] [186] [187] [188] . QOL refers to an indi vidual's subjective perception of well being, which is affected by the person's psychological status, physical health, social relationships, role (such as work) func tioning as well as sense of life satisfaction. In patients with OCD, QOL is significantly decreased in all domains (such as work, family, and social activities) [184] [185] [186] [187] [188] and, fur thermore, the relatives and caregivers of individuals with OCD also have lower QOL than healthy controls 189, 190 . Comparisons of QOL in OCD and major depression are inconsistent, but QOL in OCD has been reported to be similar to that in patients with schizophrenia [184] [185] [186] [187] . Several demographic factors including age, gender, marital status, employment status, socioeconomic sta tus, education attainment and lack of social support have been associated with QOL in OCD, although findings are somewhat inconsistent [184] [185] [186] [187] . The severity of illness, presence of comorbid depression, and certain symptom dimensions (such as hoarding) have been more con sistently associated with decreased QOL and increased functional impairment [184] [185] [186] [187] . A number of studies have indicated that depressive symptoms mediate the relation ship between OCD and impaired QOL, emphasizing the need to treat both OCD and depression when they are comorbid.
Treatment with efficacious pharmacotherapy and psychotherapy has been demonstrated to improve QOL in patients with OCD [184] [185] [186] [187] [188] . Indeed, a correlation between improvement in symptoms and improvement in QOL has been demonstrated in most studies [184] [185] [186] [187] [188] . In two large trials of SSRIs, QOL was higher in treatment responders and in those who did not relapse, suggest ing a relationship between symptomatic and functional improvement 191 . In addition, some evidence suggests an ongoing improvement in QOL with continued active treatment 192 . As in the case of depression, there has been increased awareness of the potential value of aim ing not only for treatment response in OCD, but also for symptom remission. Certainly QOL is a useful outcome measure in randomized controlled trials of OCD.
A major limitation of studies on QOL in OCD is the lack of an OCD specific measure of QOL. One study used a 69item OCD specific QOL measure and iden tified four domains specific to OCD: depression and OCD; restrictions in activities due to symptoms or avoidance; difficulties with partner and/or family due to OCD symptoms or avoidance; and self concept or coping with own illness 193 . Systematically examining the relationship of symptom dimensions, comorbid conditions, and family measures (such as family accom modation) with QOL in large samples is still required. Furthermore, the data on QOL in OCD are mostly cross sectional; studies examining the relationship between QOL and longitudinal course and outcome are needed.
Outlook
Although knowledge about OCD has greatly advanced, several obstacles remain. With regards to mechanism, most imaging studies have been single site studies with relatively small sample sizes, and replication of findings has been variable. This issue could be due to hetero geneity in the OCD samples selected, differences in imaging methods, or both factors. Moreover, although brain abnormalities are presumed to lead to dysfunc tion in specific neural processes that then lead to OCD symptoms, strong links between brain abnormalities, dysfunction in these neural processes, and specific OCD clinical profiles still need to be made. Ultimately, most imaging studies are correlational; they cannot identify whether the observed brain abnormalities cause OCD symptoms or are the result of these symptoms 57 . This issue has spurred the development of experimental ani mal systems to examine causality 44, 45 ; however, the rele vance of these animal systems to human OCD is debated (for example, whether repetitive grooming in a mouse is a valid phenotype for human OCD). Finally, even if brain abnormalities cause OCD symptoms, this does not address what caused these abnormalities. To under stand why an individual developed OCD, the field must develop a far greater understanding of how genetic risk and resilience, environmental factors, and developmental trajectory interact in humans.
With regards to diagnosis, OCD is often missed in routine clinical practice (for example, because clinicians do not ask or patients do not tell their clinician about their symptoms) or misdiagnosed and mistreated (such as being diagnosed as a psychotic disorder and treated with antipsychotic monotherapy). Improved education of the public and of front line clinicians is needed to address this problem. Moreover, the diagnosis of OCD relies on self report, and developing objective tests that confirm self report of symptoms would advance the field; for example, for brain dysfunction using imaging or neurocognitive tasks, or for behaviours using pas sive sensing technology. These tests may most profit ably focus not on the categorical diagnosis of OCD, but on component behaviours such as intrusive thoughts, repetitive behaviours, and anxiety.
Finally, although the first line treatments for OCD help up to 50% of patients achieve minimal symptoms after acute treatment, access to evidence based care var ies around the world, particularly for CBT. How to best harness technology to increase access to CBT (such as via the internet or smartphone applications 194 ) deserves further study. At the same time, because patient adher ence (to either SRIs or CBT) strongly predicts good outcome and relapse can occur once treatment stops, methods for increasing patient adherence and decreas ing relapse also deserve further study. How SRIs and CBT precisely work on the brain also requires more research 195 . The answers could help to explain why these treatments work for only some patients.
Ultimately, better (and preferably faster) treatments are needed to help more individuals with OCD achieve wellness. To meet this challenge, researchers are examin ing new classes of medications (such as glutamate modul ators and cannabinoids), different modes of neuromod ulation (such as rTMS, tDCS and DBS), new forms of psychotherapy (such as acceptance and commitment therapy), and new ways for using technology to both increase access to treatments like CBT that are already known to work and to objectively monitor treatment outcomes 194 (TaBle 1) . Ideally, such treatments would capitalize on emerging knowledge about genetic and environmental risk factors as well as the neural processes underlying obsessions and compulsions, enabling the treatment to be tailored to an individual's disease pro cess 196 . The ultimate goal will be to intervene as early and as precisely as possible to alleviate individual suffering and reduce the public health burden of this disabling illness.
One approach to address some of the issues raised above is to identify reproducible brain signatures of OCD behaviours. These brain signatures will likely reveal disease dimensions that cut across traditional diagnostic categories, potentially changing how we 197, 198 .
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